2013
Genotyping of stathmin and its association with clinical factors and survival in patients with ovarian cancer
YING L, SU D, ZHU J, MA S, KATSAROS D, YU H. Genotyping of stathmin and its association with clinical factors and survival in patients with ovarian cancer. Oncology Letters 2013, 5: 1315-1320. PMID: 23599786, PMCID: PMC3629093, DOI: 10.3892/ol.2013.1144.Peer-Reviewed Original ResearchOvarian cancerSingle nucleotide polymorphismsPlatinum-based chemotherapyEpithelial ovarian cancerFresh tumor samplesPhenotype of patientsCytoreductive surgeryClinical factorsClinical outcomesPatientsStathmin geneCancerTumor samplesHuman cancersSurgeryDirect sequencingTotalLinkage disequilibrium blockAssociationPresent studyStathminNucleotide polymorphismsOutcomesDisequilibrium blockDNA samples
1995
Ultrasensitive assay of prostate-specific antigen used for early detection of prostate cancer relapse and estimation of tumor-doubling time after radical prostatectomy.
Yu H, Diamandis E, Prestigiacomo A, Stamey T. Ultrasensitive assay of prostate-specific antigen used for early detection of prostate cancer relapse and estimation of tumor-doubling time after radical prostatectomy. Clinical Chemistry 1995, 41: 430-434. PMID: 7533672, DOI: 10.1093/clinchem/41.3.430.Peer-Reviewed Original ResearchConceptsTumor-doubling timeProstate-specific antigenProstate cancer relapseRelapse-free periodRadical prostatectomyPSA assaysCancer relapseUltrasensitive prostate specific antigenProstate cancer patientsUltrasensitive assayExponential tumor growthPSA changeCancer patientsPatientsProstatectomyTumor growthEarly detectionRelapseAntigenAssaysBasis of criteriaDaysCystoprostatectomyPostsurgerySurgery